NICE negative guidance on Faslodex

Cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has today published draft guidance for public consultation which does not recommend AstraZeneca’s (LSE: AZN) Faslodex (fulvestrant) as an option for NHS England use for delaying the growth of a particular type of breast cancer.

This is because the current evidence does not prove that it prolongs survival more than existing, less expensive treatments for specific postmenopausal women.

The drug is licensed for women who have oestrogen-receptor-positive, locally advanced breast cancer or breast cancer that has spread to other parts of the body, who have not already had treatment with hormonal therapy (aromatase inhibitors or tamoxifen).